In colon cancer, approximately 31% of samples exhibited overexpression.8 In non‐small‐cell lung cancer, approximately 70% of patients exhibited high CARD10 expression due to EGFR mutation.9 In breast cancer, 42% of cancer samples expressed a high level of CARD10, which was correlated with TNM stage,10 and in renal cell carcinoma, CARD10 expression was associated with tumour stage, size and metastasis.11 In our previous reports, we also found that 38.8% of bladder cancer tissue samples highly expressed CARD10.12 Here, CARD10 is linked to urinary bladder carcinoma.